Clinical Trial: Study to Evaluate the Efficacy and Safety of Nizubaglustat (AZ-3102) in Patients With Gaucher Disease Type 3 (GD3)

U.S., July 21 -- ClinicalTrials.gov registry received information related to the study (NCT07715084) titled 'Study to Evaluate the Efficacy and Safety of Nizubaglustat (AZ-3102) in Patients With Gaucher Disease Type 3 (GD3)' on June 08.

Brief Summary: A 96-week, open-label, Phase 2 study to evaluate the efficacy and safety of Nizubaglustat (AZ-3102) in patients with Gaucher disease type 3 (GD3).

Study Start Date: Sept. 28

Study Type: INTERVENTIONAL

Condition: Gaucher Disease Type 3

Intervention: DRUG: AZ-3102

Daily oral intake of AZ-3102 orodispersible tablets

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Azafaros B.V.

Disclaimer: Curated by HT Syndication....